SCHEMBL4489351

SCHEMBL4489351

Cc1ccc(S(=O)(=O)Oc2cccc3c(S(=O)(=O)NCC4CCCCC4)cccc23)cc1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.50
MEN1 O00255 4/20 0.50
ESR1 P03372 1/20 0.50
GAA P10253 1/20 0.50
ESR2 Q92731 1/20 0.50
NSD2 O96028 3/20 0.45
BCL2L1 Q07817 1/20 0.44
MCL1 Q07820 1/20 0.44
HTR6 P50406 1/20 0.44
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP2C9 P11712 1/20 0.42
ATM Q13315 1/20 0.41
ENPP3 O14638 1/20 0.39
ENPP1 P22413 1/20 0.39
ENPP2 Q13822 1/20 0.39
NPY5R Q15761 2/20 0.39
NPY1R P25929 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482026 0.81 CA12 (0.56) KMT2AMEN1ESR1GAAESR2
SCHEMBL4483934 0.79 MEN1 (0.52) KMT2AMEN1ESR1GAAESR2
SCHEMBL4483773 0.78 MEN1 (0.60) KMT2AMEN1ESR1GAAESR2
SCHEMBL4479900 0.77 KMT2A (0.50) KMT2AMEN1ESR1GAAESR2
SCHEMBL4473385 0.77 MEN1 (0.50) KMT2AMEN1ESR1GAAESR2
SCHEMBL4471637 0.77 NSD2 (0.56) KMT2AMEN1ESR1GAAESR2
SCHEMBL4470893 0.77 MEN1 (0.52) KMT2AMEN1ESR1GAAESR2
SCHEMBL4477941 0.76 MEN1 (0.49) KMT2AMEN1ESR1GAAESR2
SCHEMBL4483280 0.76 CYP19A1 (0.50) KMT2AMEN1ESR1GAAESR2
SCHEMBL4489698 0.76 NSD2 (0.49) KMT2AMEN1ESR1GAAESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US claimed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US claimed
US-7598418-B2 Naphthalene-1-(sulfonamide or carboxamide) derivatives; e.g. N-Benzyl-5-{[(4-methylphenyl)sulfonyl]oxy}naphthalene-1-sulfonamide; protein kinase inhibitors sensitize cancer cells to radiotherapy or anticancer agents; side effect reduction INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-10-06 US disclosed
US-20050215645-A1 Amide derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2005-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215645-A1 Amide derivatives OGG1, HDAC1, BCL2A1 KMT2A 1012/4885MEN1 4507/4885ESR1 200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.